U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Pemigatinib response

MedGen UID:
980600
•Concept ID:
CN297576
•
Sign or Symptom
Drug:
Pemigatinib
MedGen UID:
1655896
•Concept ID:
C4724807
•
Organic Chemical
An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival. [from NCI]
Pemigatinib
 
Gene (location): FGFR2 (10q26.13)

Professional guidelines

PubMed

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2024 May;99(5):946-968. Epub 2024 Mar 29 doi: 10.1002/ajh.27287. PMID: 38551368
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Freyer CW, Hughes ME, Carulli A, Bagg A, Hexner E
Expert Rev Anticancer Ther 2023 Apr;23(4):351-359. Epub 2023 Mar 29 doi: 10.1080/14737140.2023.2192930. PMID: 36927350
Novel treatment strategies for myeloproliferative neoplasms.
Bose P, Masarova L, Verstovsek S
Rinsho Ketsueki 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176. PMID: 31597841

Curated

DailyMed Drug Label, PEMAZYRE- pemigatinib tablet, 2021

Recent clinical studies

Etiology

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2024 May;99(5):946-968. Epub 2024 Mar 29 doi: 10.1002/ajh.27287. PMID: 38551368
Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma.
Gong X, Akil A, Ndi A, Ji T, Liu X, Lovern M, Chen X
CPT Pharmacometrics Syst Pharmacol 2023 Nov;12(11):1784-1794. Epub 2023 Nov 15 doi: 10.1002/psp4.13064. PMID: 37969064Free PMC Article
A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS, Bearss J, Babiker HM, Borad M
Expert Opin Drug Saf 2023 Jul-Dec;22(8):637-641. Epub 2023 Jun 26 doi: 10.1080/14740338.2023.2227561. PMID: 37363820
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Silverman IM, Hollebecque A, Friboulet L, Owens S, Newton RC, Zhen H, Féliz L, Zecchetto C, Melisi D, Burn TC
Cancer Discov 2021 Feb;11(2):326-339. Epub 2020 Nov 20 doi: 10.1158/2159-8290.CD-20-0766. PMID: 33218975
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A
Lancet Oncol 2020 May;21(5):671-684. Epub 2020 Mar 20 doi: 10.1016/S1470-2045(20)30109-1. PMID: 32203698Free PMC Article

Diagnosis

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J, Damian S, Furqan M, García-Donas J, Imai H, Italiano A, Spanggaard I, Ueno M, Yokota T, Veronese ML, Oliveira N, Li X, Gilmartin A, Schaffer M, Goyal L
Nat Med 2024 Jun;30(6):1645-1654. Epub 2024 May 6 doi: 10.1038/s41591-024-02934-7. PMID: 38710951Free PMC Article
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2024 May;99(5):946-968. Epub 2024 Mar 29 doi: 10.1002/ajh.27287. PMID: 38551368
If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ, Kato S, Sicklick JK, Lippman SM, Kurzrock R
Cancer Treat Rev 2024 Apr;125:102721. Epub 2024 Mar 21 doi: 10.1016/j.ctrv.2024.102721. PMID: 38522181Free PMC Article
Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol 2024 Jan;19(1):107-114. Epub 2024 Jan 11 doi: 10.1007/s11523-023-01024-x. PMID: 38206555
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A
Future Oncol 2020 Oct;16(30):2385-2399. Epub 2020 Jul 17 doi: 10.2217/fon-2020-0429. PMID: 32677452Free PMC Article

Therapy

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M
Ann Oncol 2022 May;33(5):522-533. Epub 2022 Feb 14 doi: 10.1016/j.annonc.2022.02.001. PMID: 35176457
Current and emerging therapies for advanced biliary tract cancers.
Kam AE, Masood A, Shroff RT
Lancet Gastroenterol Hepatol 2021 Nov;6(11):956-969. doi: 10.1016/S2468-1253(21)00171-0. PMID: 34626563
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Silverman IM, Hollebecque A, Friboulet L, Owens S, Newton RC, Zhen H, Féliz L, Zecchetto C, Melisi D, Burn TC
Cancer Discov 2021 Feb;11(2):326-339. Epub 2020 Nov 20 doi: 10.1158/2159-8290.CD-20-0766. PMID: 33218975
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A
Future Oncol 2020 Oct;16(30):2385-2399. Epub 2020 Jul 17 doi: 10.2217/fon-2020-0429. PMID: 32677452Free PMC Article
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A
Lancet Oncol 2020 May;21(5):671-684. Epub 2020 Mar 20 doi: 10.1016/S1470-2045(20)30109-1. PMID: 32203698Free PMC Article

Prognosis

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2024 May;99(5):946-968. Epub 2024 Mar 29 doi: 10.1002/ajh.27287. PMID: 38551368
Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol 2024 Jan;19(1):107-114. Epub 2024 Jan 11 doi: 10.1007/s11523-023-01024-x. PMID: 38206555
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Freyer CW, Hughes ME, Carulli A, Bagg A, Hexner E
Expert Rev Anticancer Ther 2023 Apr;23(4):351-359. Epub 2023 Mar 29 doi: 10.1080/14737140.2023.2192930. PMID: 36927350
Current and emerging therapies for advanced biliary tract cancers.
Kam AE, Masood A, Shroff RT
Lancet Gastroenterol Hepatol 2021 Nov;6(11):956-969. doi: 10.1016/S2468-1253(21)00171-0. PMID: 34626563
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A, Ricci AD, Brandi G
Cancer Treat Res Commun 2021;27:100337. Epub 2021 Feb 18 doi: 10.1016/j.ctarc.2021.100337. PMID: 33611090

Clinical prediction guides

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Lihou CF, Zhen H, Veronese ML, Abou-Alfa GK
ESMO Open 2024 Jun;9(6):103488. Epub 2024 Jun 4 doi: 10.1016/j.esmoop.2024.103488. PMID: 38838500Free PMC Article
Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol 2024 Jan;19(1):107-114. Epub 2024 Jan 11 doi: 10.1007/s11523-023-01024-x. PMID: 38206555
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Freyer CW, Hughes ME, Carulli A, Bagg A, Hexner E
Expert Rev Anticancer Ther 2023 Apr;23(4):351-359. Epub 2023 Mar 29 doi: 10.1080/14737140.2023.2192930. PMID: 36927350
Current and emerging therapies for advanced biliary tract cancers.
Kam AE, Masood A, Shroff RT
Lancet Gastroenterol Hepatol 2021 Nov;6(11):956-969. doi: 10.1016/S2468-1253(21)00171-0. PMID: 34626563
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A, Ricci AD, Brandi G
Cancer Treat Res Commun 2021;27:100337. Epub 2021 Feb 18 doi: 10.1016/j.ctarc.2021.100337. PMID: 33611090

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    Consumer resources

    Reviews

    Related information

    • Gene
      Related information in NCBI Gene
    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • OMIM(Genes)
      OMIM records containing genes associated with phenotypes registered in MedGen

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...